Colon Carcinoma Clinical Trials

5 recruiting

Colon Carcinoma Trials at a Glance

8 actively recruiting trials for colon carcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Sacramento, St Louis, and Atlanta. Lead sponsors running colon carcinoma studies include Emory University, Howard S. Hochster, MD, and Alliance for Clinical Trials in Oncology.

Browse colon carcinoma trials by phase

Treatments under study

About Colon Carcinoma Clinical Trials

Looking for clinical trials for Colon Carcinoma? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colon Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colon Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Colorectal CarcinomaStage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8+9 more
Emory University38 enrolled4 locationsNCT07405476
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Not Applicable

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Carcinoma+7 more
Alliance for Clinical Trials in Oncology420 enrolled287 locationsNCT07283939
Recruiting
Phase 2

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Colon Carcinoma
The Netherlands Cancer Institute353 enrolled6 locationsNCT03026140
Recruiting
Phase 2

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Metastatic Colon CarcinomaStage IV Colon Cancer AJCC v8Stage IVA Colon Cancer AJCC v8+2 more
Howard S. Hochster, MD42 enrolled10 locationsNCT05296681
Recruiting
Early Phase 1

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Breast CancerBladder CarcinomaEsophageal Carcinoma+11 more
Var2 Pharmaceuticals32 enrolled1 locationNCT06645808
Recruiting
Phase 2

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Stage III Colon Cancer AJCC v8Localized Colon CarcinomaStage IIB Colon Cancer AJCC v8+1 more
Emory University40 enrolled5 locationsNCT07140679
Recruiting
Not Applicable

Lymph Node Mapping Via Flourescent Dye in Colon Cancer

Lymph Node MetastasesColon Carcinoma
Universitätsklinikum Hamburg-Eppendorf30 enrolled1 locationNCT04959604